SSII_OUT_1 [2025-04-25 12:29:42 -0400] 2918 Bytes | 755 tokens | Cum: 755 tkns (9.44% of 8k)
==========================================================================

Listen up, partner—it's 12:29 PM on Fri Apr 25, 2025, and I’m revved up about SS INNOVATIONS INTL (SSII), climbing from $8.00 to $21.42. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: SS INNOVATIONS INTL (SSII)
IPO: IPO date unknown

Here’s a list of headlines for SS INNOVATIONS INTL:

Apr-24-25 08:30AM - SS Innovations to Uplist to Nasdaq
Mar-31-25 08:30AM - SS Innovations Achieves Significant Milestones in 2024
Mar-28-25 08:30AM - SS Innovations Continues its International Growth, Receiving Medical Device Regulatory Approvals for the SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine
Mar-27-25 08:30AM - SS Innovations International, Inc. Achieves Another Milestone by Successfully Performing Over 2,000 km North-to-South Robotic Cardiac Telesurgery with its SSi Mantra 3 Surgical Robotic System
Mar-13-25 08:30AM - SS Innovations Unveils Indias First Mobile Tele-Surgical Unit at SMRSC 2025
Mar-07-25 03:39PM - SS Innovations International Launches the 2nd Global Robotic Surgery Conference, SMRSC 2025

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-08-30T12:55:00Z - SS Innovations Issues Update on Status of Audit Process and Trading Market for Common Stock
B2 - 2024-05-31T12:00:00Z - SS Innovations Engages BDO as its new Auditor
B3 - 2024-04-10T12:00:00Z - SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for SS INNOVATIONS INTL (SSII).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

SSII_OUT_3 [2025-04-25 12:29:43 -0400] 726 Bytes | 198 tokens | Cum: 955 tkns (11.94% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/04/10/2860683/0/en/SS-Innovations-Flagship-SSi-Mantra-Surgical-Robotic-Device-Successfully-Completes-Telesurgery-Procedures.htmlSS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SSII_OUT_5 [2025-04-25 12:29:44 -0400] 380 Bytes | 87 tokens | Cum: 1044 tkns (13.05% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SSII_OUT_7 [2025-04-25 12:29:45 -0400] 336 Bytes | 98 tokens | Cum: 1144 tkns (14.30% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
Document A1 not found. Only 0 articles available.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SSII_OUT_9 [2025-04-25 12:29:46 -0400] 517 Bytes | 123 tokens | Cum: 1269 tkns (15.86% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S5 - 2025-04-15 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

Introduction

The Company is engaged in the business of developing, manufacturing, and selling a surgical robotic system under our proprietary brand SSi Mantra , together with allied...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SSII_OUT_11 [2025-04-25 12:29:47 -0400] 1181 Bytes | 251 tokens | Cum: 1522 tkns (19.02% of 8k)
==========================================================================

Showing S5 (chunk 1 of 6): S5:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

Introduction

The Company is engaged in the business of developing, manufacturing, and selling a surgical robotic system under our proprietary brand SSi Mantra , together with allied accessories and a wide range of surgical instruments capable of supporting cardiac and a variety of other surgical procedures under our proprietary brand SSi Mudra. Having commenced commercial sales of our surgical robotic system in the second half of 2022, the year 2023 was our first full year of commercial sales and during the year 2024, we further consolidated our installed base of SSi Mantra in various parts of India and also expanded our presence in the global markets.

Our financial performance is largely driven by increasing awareness of the benefits of robotically assisted surgery, reduced learning cu

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SSII_OUT_13 [2025-04-25 12:29:48 -0400] 1181 Bytes | 232 tokens | Cum: 1756 tkns (21.95% of 8k)
==========================================================================

Showing S5 (chunk 2 of 6): rves for robotic surgeons and the affordability and accessibility of surgical robotic technology. Our financial performance is also dependent on our obtaining regulatory approvals in various regulated markets where we have plans to sell our products. Robotically assisted surgeries are increasingly being recognized as an approved treatment modality from an insurance coverage perspective.

Our manufacturing operations being based in India derive significant operating cost advantages in terms of availability of quality and cost-effective fabrication/3D printing solutions, electronic/electrical/mechanical components, outsourced services and skilled manpower. All these factors help us in having lower costs of production which eventually helps us make our surgical robotic system cost effective and relatively affordable.

During the year ended December 31, 2024, we sold 36 surgical robotic syst

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SSII_OUT_15 [2025-04-25 12:29:49 -0400] 1181 Bytes | 280 tokens | Cum: 2038 tkns (25.47% of 8k)
==========================================================================

Showing S5 (chunk 3 of 6): ems out of which 7 systems were sold on deferred payment basis. In addition, during the year ended December 31, 2024, we also installed 11 systems on a pay-per-use basis. The system installed at the Johns Hopkins Hospital in Baltimore Maryland for research and clinical training, having completed one year period post its import into USA, was returned back to India in compliance with the Indian government regulations for medical devices exported overseas for exhibition/clinical training/research purposes. During the year ended December 31, 2024, we also received back 3 systems which, as of December 31, 2023, were installed in 3 hospitals for evaluation purposes and as such we had no systems under evaluation at any of the hospitals as on December 31, 2024. At the end of December 2024, we had a total of 62 installed systems of which 47 were installed during the year ended December 31, 2024.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SSII_OUT_17 [2025-04-25 12:29:50 -0400] 1181 Bytes | 296 tokens | Cum: 2336 tkns (29.20% of 8k)
==========================================================================

Showing S5 (chunk 4 of 6):
Results of Operations

Introduction

The financial statements appearing elsewhere in this report have been prepared assuming that the Company will continue as a going concern. The Company is still in its initial years of revenue generation by way of the sale of its product and has not yet established consistent operational revenue cash flows to meet all its fixed operating costs and hence may continue to incur losses for some time. These conditions raise doubt about the Companys ability to continue as a going concern.

The following table provides selected financial data about our Company at December 31, 2024, and December 31, 2023:

##TABLE_START Balance Sheet Data As of As of December 31, December 31, 2024 2023 Cash 466,500 2,022,276 Restricted Cash** 6,157,035 5,065,569 Total Assets 42,385,213 31,515,994 Total Liabilities 28,928,110 11,797,916 Total Shareholders Equity 13,457,103 1

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SSII_OUT_19 [2025-04-25 12:29:51 -0400] 1181 Bytes | 315 tokens | Cum: 2653 tkns (33.16% of 8k)
==========================================================================

Showing S5 (chunk 5 of 6): 9,718,078 ##TABLE_END

##TABLE_START ** Represents Fixed Deposits held by the bank as security for bank facilities and certain performance guarantees. ##TABLE_END

To date, the Company has mainly relied on debt and equity raised in private offerings to finance its operations. During 2025, the company plans to raise additional capital through further private or public offerings. However, if we are unable to do so and if we experience a shortfall in operating capital, we could be faced with having to limit our expansion plans, research and development and marketing activities.

##TABLE_START For the year ended S. No. Particulars December 31, 2024 December 31, 2023 1 Total Revenue 20,649,528 5,875,314 2 Cost of revenue (12,197,162 ) (5,149,786 ) 3 Gross profit 8,452,366 725,528 4 Research development expense 2,491,771 1,058,660 5 Stock compensation expense 14,342,784 9,723,492 6 Depreciatio

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SSII_OUT_21 [2025-04-25 12:29:52 -0400] 790 Bytes | 248 tokens | Cum: 2903 tkns (36.29% of 8k)
==========================================================================

Showing S5 (chunk 6 of 6): n and amortization expense 436,005 152,738 7 Selling, general and administrative expense 10,157,768 10,064,622 8 Loss from operations (18,975,962 ) (20,273,984 ) 9 Other income (expenses) (175,235 ) (604,308 ) 10 Income tax expense - - 11 Net loss (19,151,197 ) (20,878,292 ) ##TABLE_END

Year ended December 31, 2024, as compared to year ended December 31, 2023

Revenues. During the year ended December 31, 2024, the Company had revenues of $20,649,528 (comprising $19,457,767 of system sales, $942,54...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SSII_OUT_23 [2025-04-25 12:29:59 -0400] 6949 Bytes | 1879 tokens | Cum: 4784 tkns (59.80% of 8k)
==========================================================================

This is our set of metrics for SS INNOVATIONS INTL.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+------------------------+
| Volume: 491 | Perf Month: 75.77% | Option/Short: No / Yes | Sales Y/Y TTM: 279.04% |
+-------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 2.94K | Perf Quarter: 143.57% | Short Float: - | ROE: -115.45% |
+-------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.38 | Index: - | Short Ratio: - | ROI: -121.16% |
+-------------------+-----------------------+------------------------+------------------------+
| RSI (14): 80.92 | Market Cap: 3.30B | Short Interest: - | Sales Surprise: - |
+-------------------+-----------------------+------------------------+------------------------+
| ATR (14): 1.41 | Shs Outstand: 171.58M | Beta: - | EPS Surprise: - |
+-------------------+-----------------------+------------------------+------------------------+
| SMA20: 77.40% | Shs Float: 7.44M | Sales Q/Q: 495.95% | P/E: - |
+-------------------+-----------------------+------------------------+------------------------+
| SMA50: 82.09% | Inst Own: - | Sales past 5Y: 111.87% | Earnings: - |
+-------------------+-----------------------+------------------------+------------------------+
| SMA200: 200.31% | Insider Own: 96.16% | Employees: 378 | |
+-------------------+-----------------------+------------------------+------------------------+
| Perf Week: 94.86% | Insider Trans: - | Debt/Eq: 1.35 | |
+-------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading by SS INNOVATIONS INTL officers or majority shareholders (if available).

Inside Trans: SS Innovations International, Inc. (SSII) by SRIVASTAVA SUDHIR (Chairman and CEO) on 2025-04-24
- Common Stock, $0.0001 par value: 10000 shares at $0 (I)
- Common Stock, $0.0001 par value: 5000 shares at $0 (I)

Inside Trans: SS Innovations International, Inc. (SSII) by Cohen Barry F (COO - Americas) on 2025-04-17
- Common Stock: 100 shares at $8.75 (D)
- Common Stock: 100 shares at $8.9 (D)
- Common Stock: 226 shares at $9 (D)

Inside Trans: SS Innovations International, Inc. (SSII) by SRIVASTAVA SUDHIR (Chairman and CEO) on 2025-04-15
- Common Stock, $0.0001 par value: 10000 shares at $0 (I)

Inside Trans: SS Innovations International, Inc. (SSII) by Cohen Barry F (COO - Americas) on 2025-04-14
- Common Stock: 103 shares at $8.93 (D)
- Common Stock: 107 shares at $9.5 (D)

Inside Trans: SS Innovations International, Inc. (SSII) by Cohen Barry F (COO - Americas) on 2025-04-08
- Common Stock: 500 shares at $9.16 (D)
- Common Stock: 200 shares at $8.95 (D)
- Common Stock: 100 shares at $7.5 (D)
- Common Stock: 200 shares at $8.93 (D)

Inside Trans: SS Innovations International, Inc. (SSII) by SRIVASTAVA SUDHIR (Chairman and CEO) on 2025-03-31
- Common Stock, $0.0001 par value: 5811554 shares at $1.38 (I)
- Common Stock, $0.0001 par value: 165000 shares at $0 (I)
- 7% Convertible One-Year Promissory Note: 1 shares at $N/A (I)

Inside Trans: SS Innovations International, Inc. (SSII) by Cohen Barry F (COO - Americas) on 2025-03-31
- Common Stock: 100 shares at $10 (D)
- Common Stock: 570 shares at $9.4 (D)
- Common Stock: 500 shares at $10 (D)
- Common Stock: 1500 shares at $9.75 (D)
- Common Stock: 420 shares at $9.2 (D)

Inside Trans: SS Innovations International, Inc. (SSII) by SRIVASTAVA SUDHIR (Chairman and CEO) on 2025-03-19
- 7% Convertible One-Year Promissory Note: 1 shares at $8000000 (I)

Inside Trans: SS Innovations International, Inc. (SSII) by Anup Kumar Sethi (CFO) on 2025-03-07
- Common Stock, $0.0001 par value: 20000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 20
Average Volume: 5640.26
30-Day High: 20
30-Day Low: 8
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of SS INNOVATIONS INTL (SSII).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about SS INNOVATIONS INTL.

2) MARKET_SCORE[]
This conversation was initiated because SSII is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for SSII.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, SSII could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect SSII to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of SS INNOVATIONS INTL.

11) ETHICAL_RATING[]
Rate SS INNOVATIONS INTL’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of SS INNOVATIONS INTL.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

SSII_IN_25 [2025-04-25 12:29:59 -0400] 126 Bytes | 29 tokens | Cum: 5029 tkns (62.86% of 8k)
==========================================================================

====================================
[2025-04-25 12:29:59] # Analysis Completed
Elapsed Time: 18.00 seconds